Treatment (T) of metastatic colorectal cancer (mCRC) patients (pts) ≥75 years (y) old in clinical practice: A multicenter analysis.

e14514 Background: CRC pts have a median age of incidence > 65y although they are largely under-represented in phase III trials. This large population contains pts unfit for T, those suitable for monotherapy or for doublets and the impact of chemotherapy (CHT) outside clinical trial is unclear. Aim of the study was to retrospectively analyse T of elderly mCRC pts. Methods: Kaplan-Meir method was used for OS, the log-rank or Tarone-Ware test for differences between subgroups, Cox’s proportional hazard model to assess the impact of known prognostic factors and T. Results: 751 pts with mCRC observed from January 2000 to January 2013 were collected. Median age was 79y (75-93);<80y 58.1%, 80-84y 32.1%, ≥84y 9.2%; M/F 61/39%, ECOG PS:0-1/2-3 85/15%, colon/rectum 74/26%; multiple metastatic sites 34%, only liver 41% of pts. KRAS status was studied in 35% of pts with 44% mutated (M); 20,5% of pts were untreated including surgery (33% of pts ≥80y). Comorbidities: cardiovascular 34%, diabetes 14%, hypertension 50%....